Mobile fractions (Mf) and exchange half-lives (t1/2) of titin-eGFP (FRAP analysis)
| Treatment or cell type | Mf [%] | t1/2 [h] |
| Control | 49 ± 4 | 2.1 ± 0.4 |
| CX | 53 ± 9 | 2.6 ± 0.4 |
| LCa | 72 ± 4** | 3.6 ± 0.6 |
| HCa | 28 ± 5* | 2.9 ± 0.9 |
| BDM | 38 ± 1 | 2.3 ± 0.3 |
| BDM + HCa | 24 ± 1* | 1.7 ± 0.8 |
| NCM | 56 ± 3 | 3.7 ± 0.4 |
| Treatment or cell type | Mf [%] | t1/2 [h] |
| Control | 49 ± 4 | 2.1 ± 0.4 |
| CX | 53 ± 9 | 2.6 ± 0.4 |
| LCa | 72 ± 4** | 3.6 ± 0.6 |
| HCa | 28 ± 5* | 2.9 ± 0.9 |
| BDM | 38 ± 1 | 2.3 ± 0.3 |
| BDM + HCa | 24 ± 1* | 1.7 ± 0.8 |
| NCM | 56 ± 3 | 3.7 ± 0.4 |
Control, embryonic cardiomyocytes without treatment at normal calcium (NCa); CX, cycloheximide treatment; LCa, low calcium concentration; HCa, high calcium concentration; BDM, 2,3-butanedione monoxime; NCM, neonatal cardiomyocytes (n = 24).
*, P < 0.05.
**, P < 0.01; one-way ANOVA, posttest Dunnett (comparison vs. control). Data are indicated as means ± SEM.